Astria Therapeutics, Inc.

NasdaqGM:ATXS Stock Report

Market Cap: US$504.1m

Astria Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jill Milne

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage20.4%
CEO tenure16yrs
CEO ownership0.008%
Management average tenure4.3yrs
Board average tenure8.7yrs

Recent management updates

Recent updates

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Dec 10
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Jul 27
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Apr 03
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10
Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

CEO Compensation Analysis

How has Jill Milne's remuneration changed compared to Astria Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$3mUS$602k

-US$73m

Sep 30 2023n/an/a

-US$55m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$2mUS$568k

-US$52m

Sep 30 2022n/an/a

-US$48m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$65m

Dec 31 2021US$3mUS$536k

-US$219m

Sep 30 2021n/an/a

-US$219m

Jun 30 2021n/an/a

-US$222m

Mar 31 2021n/an/a

-US$199m

Dec 31 2020US$1mUS$520k

-US$37m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$1mUS$501k

-US$26m

Sep 30 2019n/an/a

-US$26m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$24m

Dec 31 2018US$1mUS$476k

-US$26m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$27m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$633kUS$462k

-US$27m

Compensation vs Market: Jill's total compensation ($USD2.96M) is about average for companies of similar size in the US market ($USD2.46M).

Compensation vs Earnings: Jill's compensation has increased whilst the company is unprofitable.

CEO

Jill Milne (56 yo)

16yrs

Tenure

US$2,955,504

Compensation

Ms. Jill C. Milne, PhD is a Co-founder of Astria Therapeutics, Inc. (formerly known as Catabasis Pharmaceuticals, Inc.), has been its Director, President and Chief Executive Officer since June 2008. She se...

Leadership Team

NamePositionTenureCompensationOwnership
Jill Milne
Co-Founder16yrsUS$2.96m0.0080%
$ 40.2k
Noah Clauser
CFO & Treasurer4.5yrsUS$1.35m0%
$ 0
Christopher Morabito
Chief Medical Officer1.9yrsUS$1.32m0%
$ 0
Benjamin Harshbarger
Chief Legal Officer4yrsUS$845.83k0%
$ 0
Keri McGrail
Senior Vice President of Human Resources3.2yrsno datano data
Andrea Matthews
Chief Business Officer6.8yrsno datano data
Andrew Komjathy
Chief Commercial Officer4.8yrsno datano data
John Ruesch
Senior Vice President of Pharmaceutical Sciences & Technical Operationsless than a yearno datano data

4.3yrs

Average Tenure

54yo

Average Age

Experienced Management: ATXS's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jill Milne
Co-Founder16yrsUS$2.96m0.0080%
$ 40.2k
Michael Kishbauch
Independent Director8.2yrsUS$157.67k0%
$ 0
Edward Scolnick
Member of Scientific Advisory Boardno datano datano data
Kenneth Bate
Independent Chairman of the Board10.4yrsUS$194.17kno data
Arthur Rubenstein
Member of Scientific Advisory Boardno datano datano data
Gregory Lapointe
Independent Director5.4yrsUS$163.67k0%
$ 0
Johannes Jacob Kastelein
Member of Scientific Advisory Boardno datano datano data
Michael Jirousek
Member of Scientific Advisory Board8.7yrsUS$589.63kno data
Jay Horton
Member of Scientific Advisory Boardno datano datano data
Roger Ulrich
Member of Scientific Advisory Boardno datano datano data
Eric Brass
Member of Scientific Advisory Boardno datano datano data
Sekar Kathiresan
Member of Scientific Advisory Boardno datano datano data

8.7yrs

Average Tenure

70yo

Average Age

Experienced Board: ATXS's board of directors are considered experienced (8.7 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.